ORIGINAL ARTICLE |
|
Year : 2012 | Volume
: 18
| Issue : 3 | Page : 326-331 |
|
Pharmacogenetic typing for oral anti-coagulant response among factor V Leiden mutation carriers
Risha Nahar1, Renu Saxena2, Roumi Deb3, Ishwar C Verma2
1 Centre of Medical Genetics, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi; Amity Institute of Biotechnology, Amity University, Uttar Pradesh, India 2 Centre of Medical Genetics, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India 3 Amity Institute of Biotechnology, Amity University, Uttar Pradesh, India
Correspondence Address:
Ishwar C Verma Director, Center of Medical Genetics, Sir Ganga Ram Hospital, Rajinder Nagar - 110 060, New Delhi India
Source of Support: The research fund for the above work was granted by Sir Ganga Ram Hospital, New Delhi, India, Conflict of Interest: None | 2 |
DOI: 10.4103/0971-6866.107987
|
|
Context: Factor V Leiden mutation is the most common inherited predisposition for hypercoagulability and thereby a common genetic cause for initiation of oral anti-coagulation therapy. There is a dearth of knowledge of coumarin response profile in such thrombophilic population.
Aims: The current pilot study aims to estimate coumarin sensitivity in an Indian cohort with an inherited thrombophilia risk factor (Factor V Leiden mutation carriers) based on the observed frequency of CYP2C9 *2, *3 and VKORC1-1639G >A genotype combinations.
Settings and Design: A retrospective study carried out in a tertiary health care center in India.
Materials and Methods: Carriers of FVL mutation were genotyped for CYP2C9 (*2, *3) and VKORC1 (-1639G >A) variants by PCR-RFLP technique.
Statistical Analysis Used: Chi-square test to analyze difference in expected and observed genotype frequency.
Results: Sixty-one (n = 61) unrelated carriers of FVL mutation were observed in the 13 years study period. The allele frequency of CYP2C9 *2, CYP2C9 *3, and VKORC1-1639A in this cohort was 0.06, 0.11, and 0.16, respectively. Six (9.7%) individuals had two of the three variant alleles (heterozygous or homozygous), and 28 (45.9%) were heterozygous for at least one polymorphism.
Conclusions: Pre-prescription genotyping for coumarin drugs, if introduced in Indians with inherited thrombophilia (in whom oral anti-coagulant therapy may be necessary), is likely to identify 9.7% (hypersensitive) subjects in whom the optimum anti-coagulation may be achieved with reduced dosages, 44.3% (normal sensitivity) who may require higher dose and also 55.6% (hyper and moderate sensitivity) subjects who are likely to experience bleeding episodes. |
|
|
|
[FULL TEXT] [PDF]* |
|
|
|